{"nctId":"NCT01950260","briefTitle":"Early Levothyroxine Post Radioactive Iodine","startDateStruct":{"date":"2013-09","type":"ACTUAL"},"conditions":["Graves' Disease"],"count":61,"armGroups":[{"label":"Levothyroxine","type":"EXPERIMENTAL","interventionNames":["Drug: Levothyroxine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Levothyroxine","otherNames":["Thyroid hormone"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n-all adult patients (ages 18-70 years) with Graves' Disease (GD) who will receive radioactive iodine (RAI) ablation of the thyroid gland for treatment of GD\n\nExclusion criteria:\n\n* clinically manifest Graves' ophthalmopathy (GO)\n* recent (\\<1 yr.) history of arrhythmias or any history of ventricular arrhythmias\n* preexistent cardiomyopathy\n* malnutrition\n* psychiatric history that could get worse if patient remains persistently hyperthyroid\n* unlikely to return for the planned follow-up visits\n* unlikely to comply with the blood drawing schedule\n* unlikely to complete the hypothyroid-Health Related Quality of Life (HDQL) and Thyroid Specific (TSQ) questionnaires","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Overt Hypothyroidism","description":"Incidence of overt hypothyroidism at 8 weeks post radioactive iodine treatment (RAI). Overt hypothyroidism was defined as thyroid stimulating hormone (TSH) test result \\> 3.0 milliunits per liter (mIU/L) or thyroid hormone free T4 (fT4) \\< 0.8 nanograms per deciliter (ng/dL). Free T4 is the portion of total T4 thyroid hormone that is available to your tissues in your bloodstream.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hypothyroid-Health Related Quality of Life","description":"The mean change in Quality of life scores was measured by the Hypothyroid-Health Related Quality of Life (HRQL) questionnaire. This questionnaire consists of 27 questions specifying the severity of the discomfort or symptoms of hypothyroidism using a 5 point scale for each question with \"not at all\"=1 to \"all the time\"=5. Higher scores are associated with a lower quality of life. The change between weeks 4 and 8 were assessed using a hierarchical linear model. The primary parameter of interest from the model was the treatment by time interaction term. Time was a collection of indicator values representing each assessment point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":"28.4"},{"groupId":"OG001","value":"19.8","spread":"25.0"}]}]}]},{"type":"SECONDARY","title":"Change in Thyroid Specific Quality of Life","description":"The mean change in quality of life scores was measured by the Thyroid Specific Questionnaire (TSQ). This questionnaire consists of 12 questions ranked on a four-point scale for each question where 0 is 'better than usual' and 3 is 'much less than usual'. A higher score indicates higher levels of dissatisfaction and a lower quality of life. The change between weeks 4 and 8 were assessed using a hierarchical linear model. The primary parameter of interest from the model was the treatment by time interaction term. Time was a collection of indicator values representing each assessment point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"12.8"},{"groupId":"OG001","value":"-3.8","spread":"8.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":30},"commonTop":["Palpitations"]}}}